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Introduction
Invasive fetal therapy has thrived since the advent and
development of ultrasound after Sir Albert Liley published
his now-classic report regarding fetal transfusion in
1963 [1]. The appearance of another milestone, success-
ful shunt treatment of fetal obstructive uropathy in
1987, marked the maturation of invasive techniques
assisted by ultrasound [2]. Prompt antenatal treatments
thus provide effective alternatives to termination for va-
rious fetal structural anomalies. Meanwhile, fetal sur-
gery, whether endoscopic or open, for various fetal mal-
formations including congenital cystadenomatoid mal-
formation (CCAM), open neural tube defects, obstruc-
tive uropathy and congenital diaphragmatic hernia
(CDH) developed from the 1980s and attracted a lot of
attention [3–6]. Professional societies and organizations
focusing on fetal therapy were also organized, such as
the International Fetal Medicine and Surgery Society
(IFMSS) and the International Society of the Fetus as
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a Patient, reflecting the life of this emerging highly
specialized profession. The authors give a concise intro-
duction to invasive fetal therapy here because it is im-
possible to cover the fascinating history and develop-
ment of this challenging field. The article adopts a main-
ly disease-, rather than procedure-, oriented layout to
enhance readability.
Accumulation of Excessive Fluid in
Obstructive Fetal Diseases
Excessive fluid accumulation often results in irreversible
damage to developing fetal organs by compressing the
parenchyma of adjacent organs. Prompt decompression
is thus mandatory. Aspiration and shunt placement are
frequently the treatment modalities of choice.
Obstructive uropathy
Fetal obstructive uropathies represent a wide variety
of entities involving the upper and lower urinary tract.
Detailed discussion of the diagnostic criteria for these
disorders is omitted here, but interested readers should
refer to the review by Johnson and Freeman [7]. Ob-
struction leading to oligohydramnios (i.e. fetal anuria
because of obstructive uropathy) may require antenatal
intervention.
Common obstructive fetal uropathies can be
classified into upper (UUTO) and lower urinary tract
obstructions (LUTO). Ureteropelvic junction stenosis
(UPJS) is the most common cause of postnatal hydro-
nephrosis, followed by reflux, vesicoureteral junction
stenosis (VUJS) and posterior urethral valve. Urinary
diversion is necessary for oligohydramnios or when
there is evidence of progressive nephropathy diagnosed
by fetal urine sampling. Markers used for evaluation of
fetal renal function include sodium (< 100 mg/dL),
chloride (< 90 mg/dL), osmolality (< 200 mOsm/L),
calcium (< 8 mg/dL), ` 2-microglobulin (< 6 mg/dL) and
total protein (< 20 mg/dL) [7].
Vesicoamniotic shunting is currently the standard
treatment for LUTO [2]. The most widely used shunting
instruments approved by the US Food and Drug Ad-
ministration for human use include a British-made,
Rodeck-style double-pigtailed shunt (Rocket Medical
Plc, Watford, Herts, UK) and an American-made
Harrison fetal bladder stent set (HFBS; Cook Obgyn®,
Spencer, IN, USA).
Complications, including migration, dislodgment
and displacement of the shunt, have led to the emer-
gence of a new promising technique, fetal cystoscopic
ablation of the posterior urethral valve, to alleviate the
obstruction, although it is still experimental [8].
Fetal pleural effusion
Congenital chylothorax occurs in 1 in every 12,000–
15,000 pregnancies and is the most common form of
pleural effusion encountered in the perinatal period [9,
10]. It is associated with fetal pulmonary hypoplasia,
especially if it develops in the second trimester as a re-
sult of impaired fetal lung growth due to compression. A
lymphocyte count of more than 85% in the pleural fluid
is suggestive of the diagnosis. The pleural fluid is straw-
colored. Antenatal treatment includes maternal diet-
ary modification [11], repeated thoracocentesis [12],
thoracoamniotic shunting [13], and pleurodesis with
OK-432 (Picibanil®, Chugai Pharmaceutical Co, Tokyo,
Japan) [14–17], a lyophilized incubation mixture of
group A Streptococcus pyogenes of human origin, or
maternal blood [10]. The perinatal mortality rate varies
in different series from 15% to 53% [10,16,18,19] and
prognosis is poorer if the disease is associated with
hydrops fetalis, bilaterality or preterm delivery.
Non-chylous fetal pleural effusion is extremely rare
and treatment should be aimed at correcting the under-
lying disorder (e.g. fetal transfusion for fetal anemia
or intravenous immunoglobulin for viral infections) as
well as providing decompression. Several Taiwanese
obstetricians have made significant efforts to tackle this
condition [12,13,17].
Fetal ascites
Fetal ascites can be part of the clinical presentation of
hydrops fetalis or an isolated finding in the antepartum
period. Treating the underlying causes of hydrops feta-
lis is the best therapy when fetal ascites is part of the
clinical spectrum of hydrops fetalis. However, aggressive
aspiration of fetal ascites is controversial. The perinatal
outcome is good if meconium ascites is not present [20,
21]. Pleural effusion may develop when fluid has effused
through the diaphragm from massive ascites, when pa-
racentesis may be indicated. We have encountered mas-
sive ascites caused by meconium leakage that needed
to be aspirated regularly to keep the fetus free from effu-
sive hydrothorax. The outcome of that baby was excel-
lent [unpublished data].
Hydrops fetalis
Fetal hydrops can be classified as immune or non-
immune. Immune hydrops fetalis often results from ma-
ternal alloimmunization to fetal antigens. Progressive
fetal anemia results in fetal cardiac failure, hydrops
fetalis and death. The prevalence of rhesus isoimmuni-
zation in Caucasians promoted the rapid development
of fetal transfusion to tackle the disease in the West. Sir
Albert Liley was the first to use intraperitoneal trans-
fusion, and since then, intravascular transfusion has
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become the treatment of choice with the assistance of
sophisticated ultrasound [1,22].
In Scotland, the incidence of non-immune hydrops
fetalis is 1 in 830 deliveries; 35% of the cases remained
idiopathic despite extensive antenatal and postnatal
investigations [23]. Viral infection, cardiovascular ab-
normalities, twin-twin transfusion syndrome (TTTS),
chromosomal abnormalities and fetomaternal hemor-
rhage accounted for most of the 65% of cases for which
etiologies were elucidated. Intravascular transfusion
improves the outcome of this previously lethal disorder
[23].
It is extremely rare for rhesus isoimmunization to be
found in ethnic Chinese populations. Non-immune hy-
drops fetalis, especially homozygotic _-thalassemia-1,
comprises the majority of hydrops fetalis in Taiwan
[24]. However, a substantial number of non-immune
hydrops fetalis cases that are categorized as idiopathic
may be due to human parvovirus B19 infection, since
human parvovirus B19 is not regularly tested for in Tai-
wan. Fetal transfusion will certainly help these patients
[25].
Fetal hydrocephalus
Early shunting in the neonatal period improves both the
survival and long-term prognosis in hydrocephalic infants
and, therefore, investigators used an in utero catheter
shunt (one-way-valved ventriculoamniotic shunt) to
treat fetal hydrocephalus. However, of the 34 infants
(83%) who survived, only 12 (35.3%) developed normally
[26]. Meanwhile, the sole manufacturer of the one
ventricular shunt available for clinical use discontinued
production of the device as a result of decreasing
demand. Therefore, invasive fetal shunt therapy is not
currently recommended.
Disorders of Amniotic Fluid Volume
Polyhydramnios
Polyhydramnios is defined as an amniotic fluid index
(AFI) of more than 25 cm or maximal vertical pool depth
(MVPD) of more than 8 cm. Cases can be further clas-
sified as mild (MVPD, 8–12 cm), moderate (MVPD, 12–
15 cm) or severe (MVPD, * 15 cm). Severe polyhydram-
nios may produce maternal abdominal discomfort,
respiratory embarrassment, renal failure and uterine
irritability (which will result in preterm delivery). There
is a 5% chance of aneuploidy, so karyotyping is some-
times indicated.
The criteria for amnioreduction, as adopted by
Professor Fisk’s group in London, are an AFI of more
than 40 cm or an MVPD of more than 12 cm [27]. An
easy formula shows how much amniotic fluid needs to
be drained: a 1 cm decrease in AFI corresponds to a
need to remove 100 mL of amniotic fluid [28]. Prosta-
glandin synthetase inhibitors, including indometha-
cin and sulindac, are used to alleviate polyhydramnios
because they can reduce hourly fetal urine production.
Sulindac is safer than indomethacin with regard to the
side effect of in utero premature closure of the ductus
arteriosus [27].
Oligohydramnios
Oligohydramnios is noted in 3–5% of pregnancies in the
third trimester but only in 0.2% in the midtrimester. It is
defined as an AFI of less than 5 cm or an MVPD of less
than 2 cm [27]. Oligohydramnios may be associated
with increased perinatal morbidity and mortality ex-
cept in isolated oligohydramnios that develops near
term [29]. A variety of conditions, including membrane
rupture, fetal urinary tract abnormalities such as mega-
cystis caused by posterior urethral valve, and pre-
renal abnormalities involving uteroplacental insuffi-
ciency, can result in oligohydramnios [30]. Amnioin-
fusion is used antepartum to prolong the gestation as
well as to reduce the sequelae of Potter sequence, in-
cluding fetal growth restriction, pulmonary hypoplasia,
limb deformity and amniotic band syndrome [31]. Mean-
while, intrapartum amnioinfusion can reduce the cesa-
rean rate, meconium aspiration syndrome, umbilical
acidosis (pH < 7.1) and low Apgar score at 5 minutes
[32]. We have also used serial transabdominal antepar-
tum amnioinfusion with warm lactate Ringer’s solution
with a hard spinal needle in a number of patients and
the results seem favorable [unpublished data].
Open Neural Tube Defects
Spina bifida and meningomyelocele result from failure
of the closure of the midline bony defect and failure of
caudal neurulation during the fourth week of gestation.
Intrauterine closure of the exposed spinal cord tissue
prevents secondary neurologic injury in animals with a
surgically created spinal defect. The two-hit hypothesis
(embryologic error plus secondary injury of nervous
tissue by chemicals in the amniotic fluid) was therefore
accepted from the growing experimental evidence [33].
Chiari II malformation, including herniation of the cere-
bellum and hindbrain, is usually present and is associ-
ated with hydrocephalus. Many children with meningo-
myelocele manifest developmental delay and learn-
ing disabilities. A ventriculoperitoneal (VP) shunt is
usually necessary for patients with hydrocephalus. Bru-
ner et al published their experience of treating fetal
M. Chen, C.P. Chen
Taiwanese J Obstet Gynecol • December 2004 • Vol 43 • No 4188
myelomeningocele using fetal surgery and the outcome
in their patients [34]. Their data showed a decrease in
the incidence of hindbrain herniation and shunt-
dependent hydrocephalus in infants with spina bifida.
However, the motor and sensory nervous dysfunction in
the lower extremities as well as in genitourinary systems
showed little improvement.
Placental and Fetal Tumors
Chorioangioma
Chorioangioma is a benign placental vascular tumor
and is regarded as a harmatoma. Most cases are typical
capillary hemangiomas arising from just beneath
the chorionic plate. The incidence is about 1% of all pla-
centas. Chorioangiomas that are large enough to be vi-
sualized by ultrasound are uncommon, accounting for
only 1 in 3,500–9,000 births [35]. Complications of
chorioangiomas arise only when the tumors are larger
than 4–5 cm in diameter. The arteriovenous (AV) shunt
produced by the tumor causes progressive fetal cardiac
failure. Hydrops fetalis, polyhydramnios, preterm deliv-
ery and pre-eclampsia develop thereafter. Nicolini et al
were the first to inject 100% alcohol into the large veins
of the tumors, producing two healthy infants [36].
Several other authors followed [35]. Alcoholization of
placental tumors is now a promising and easy treatment
modality. Alcohol spillage is a theoretical fear, although
no cases have been observed.
Cystic hygroma
Cystic hygromas are congenital malformations of the
lymphatic system and consist of dilated endothelium-
lined space. Infections and/or chemical irritants can
damage the endothelial lining. OK-432 has been used
to treat pediatric and adult cystic hygroma and is wide-
ly accepted [37]. OK-432 is well known as a biologic re-
sponse modifier with anti-tumor effects. Some research-
ers, mostly from Japan, have used it in treating neona-
tal and even fetal cystic hygroma with some success
[38–43]. The pathway of action of OK-432 within the
cystic hygroma is thought to be cellular and cytokine-
mediated [41]. The elevated cytokine levels probably
increase the permeability of the vascular endothelium
within the cystic hygroma. Leukocytes are recruited and
the local inflammatory reaction further increases the
permeability of the lining endothelium and accelerates
drainage of the accumulated lymph. Involution of the
tumor then ensues [41]. An 81.5% fetal demise rate has
been observed in fetuses with cystic hygroma [44]. The
prognosis is poorer if the condition is associated with
chromosomal abnormalities, hydrops fetalis or struc-
tural abnormalities, although a case of spontaneous
regression of hydrops fetalis and cystic hygroma after
birth has been reported [40,45]. Three reported cases
have successfully been treated antenatally with OK-432,
but only the case from our group was associated with
hydrops fetalis [17,42,43]. Three other cases with fetal
cystic hygroma and hydrops fetalis receiving antenatal
OK-432 injection died in utero or within 1 month after
birth [39,40]. Thus, our result seems to be satisfactory
when compared to others [17].
Sacrococcygeal teratoma
Sacrococcygeal teratoma may steal fetal circulation with
a large AV shunt and causes fetal cardiac failure. Thus,
antenatal intervention may be indicated when the tumor
is growing very fast, when the absolute size is large or
when fetal cardiac failure is obvious. Open fetal surgery
was first tried by a team led by Dr. Harrison, the most
respected fetal surgeon in the world, in the late 1980s,
but considerable fetal death or preterm delivery hampered
its development [46]. Radiofrequency ablation, absolute
alcohol injection and fetoscopic resection gradually
replaced open fetal surgery. Ablation of feeder vessels is
the main goal of antenatal treatment. Complete resection
of the tumor can be reserved until after birth [47].
Congenital cystadenomatoid malformation and
other space-occupying lung lesions
CCAM, bronchogenic cyst and bronchopulmonary se-
questration are common space-occupying lesions that
may hamper fetal lung development, impair venous
return followed by hydrops fetalis and adversely affect
perinatal outcome. Thoracoamniotic shunting is some-
times helpful when the lesions are cystic. However, ex-
cision of the tumor or even fetal lobectomy is indicated
when lesions are not cystic [48,49]. Thorpe-Beeston
and Nicolaides reported that the prognosis of antenatally
diagnosed CCAM is excellent in the absence of signs of
severe fetal distress [50]. The need for surgery should be
judged on appropriate postnatal investigations rather
than antenatal prognostic markers [51], which down-
grade the value of fetal surgery.
Complications of Monochorionic
Multiple Pregnancies
Although Taiwan provides excellent medical care,
fetoscopy is largely unavailable. This lack makes the
progress of a truly innovative fetal therapy elusive.
However, we will describe the current state of fetoscopy
as well as its main application: treating complications
of monochorionic multiple pregnancies, especially the
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TTTS and twin reversed arterial perfusion sequence
(TRAP; the so-called acardiac monster). Alternatives to
fetoscopy are discussed.
Fetoscopy
There are two types of fetoscopy: obstetric endoscopy
and endoscopic fetal surgery [52]. Obstetric endoscopy
deals with the placenta, umbilical cord and fetal mem-
branes. Laser coagulation (using an Nd-YAG laser) of
placental vessels in TTTS and cord occlusion in mono-
chorionic pregnancy are the most common applications.
Endoscopic fetal surgery deals with in utero fetal surgery
and remains highly experimental. Fiber optic rather
than rod lens fetoscopes with scope diameters between
1.2 and 2 mm and an external sheath of approximately
3 mm are used. Hartmann solution or other isotonic
electrolyte solutions can be used for amnioinfusion to
distend the uterine cavity and to enhance the working
area for fetoscopy. A single-port system is favored over
multiple ports because it leads to fewer complications
such as preterm delivery and preterm premature rupture
of fetal membranes (PPROM). Procedures should be
practiced on animal models, especially sheep, before
performing them in human fetuses. The Eurofoetus
group in Europe, three leading centers in London (led by
Rodeck, Fisk and Nicolaides) and some centers in the
USA (e.g. Quintero in Florida, Evans at Wayne State, De
Lia in Milwaukee, Adzick in Philadelphia, and Harrison
in San Francisco) and Japan regularly perform advanced
fetoscopic procedures.
Twin-twin transfusion syndrome
TTTS occurs in 15% of monochorionic twin pregnancies.
Perinatal loss exceeds 80% if left untreated. However,
overall perinatal survival rates (usually only one twin
survives) improve to around two-thirds with a variety of
treatment modalities including amnioreduction [53],
septostomy [54], selective reduction and laser ablation
of the communicating vessels. Diagnosis of TTTS in-
cludes a polyhydramnios-oligohydramnios sequence as
well as other minor ultrasound findings such as stuck
twin, discordant twin and the cocoon sign [55,56].
Quintero et al classified TTTS into the widely used
five stages based on severity: Stage I, bladder of the
donor visible, normal Doppler; Stage II, bladder of the
donor invisible, normal Doppler; Stage III, critically
abnormal Doppler in either twin; Stage IV, hydrops
fetalis; and Stage V, demise of one or both twins [57].
Monochorionic placentae are characterized by a certain
degree of sharing of one or more cotyledons by the
two fetal circulations. Some authors therefore regard
the imbalance of intertwin transfusion (AV communi-
cation) as the cause of TTTS; however, artery–artery
(AA) communication usually confers protection against
TTTS. In other words, communication between two
fetal circulations is almost universal in monochorionic
twins, but asymmetric AV communication may result in
TTTS [58]. The result of treating TTTS is unsatisfac-
tory, which may be due to a lack of understanding of
the placenta. However, since the Eurofoetus group pub-
lished their data comparing serial amnioreduction with/
without septostomy versus fetoscopic laser coagulation
of communicating vessels, fetoscopic laser coagulation
has gradually become the treatment of choice in TTTS
[59,60]. Hecher et al showed comparable fetal survival
(61% in laser group vs 51% in amnioreduction group)
but a much lower incidence of abnormal ultrasound
findings in the neonatal brain (6% in laser group vs 18%
in amnioreduction group) with laser coagulation com-
pared with amnioreduction [59]. However, there is a
procedure-related fetal loss rate of 15–50% in fetosco-
pic laser coagulation, so amnioreduction still has a role
in Stage I–II TTTS [56].
Selective feticide is indicated when one twin is about
to die, because the living twin will exsanguinate into the
dead twin, resulting in anemia and ischemic changes in
the brain. Quintero et al demonstrated this phenomenon
with fetoscopy by visualizating the dead as well as the
living twin within 3 hours of the demise of the donor
twin [61]. Thus, selective feticide may be helpful in pre-
venting exsanguination. Routes for feticide include the
intrafetal and funicular approaches. Injection with po-
tassium chloride, xylocaine, enbucrilate gel and abso-
lute alcohol under ultrasound guidance is an easy but
less effective approach [62]. Radiofrequency ablation
[63], monopolar coagulation, bipolar coagulation and
cord ligation are more effective but also more expensive.
The option chosen depends on local conditions. Selective
feticide is less effective in TTTS than TRAP because the
flow rate in the fetal circulation is much higher in TTTS
than in TRAP [60].
Twin reversed arterial perfusion sequence
TRAP is a unique complication of monochorionic twin-
ning and is extremely rare. The incidence of TRAP is only
1 in 35,000 deliveries, 1 in 100 monozygotic twins and
1 in 30 monozygotic triplets [64]. Selective reduction of
the acardiac twin is indicated in the presence of poor
prognostic factors, including an acardiac-to-pump twin
weight ratio of * 70%, congestive heart failure or hy-
drops in the pump twin, polyhydramnios, anceps acar-
dia or presence of arms in the acardiac twin. The overall
perinatal mortality of the pump twin is around 35%.
Treatment modalities include embolization, cord liga-
tion by fetoscopy, laser coagulation, bipolar diathermy
and monopolar diathermy. A group at Chang Gung Me-
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morial Hospital, Taiwan, successfully treated an acardiac
acephalus twin using monopolar thermocoagulation
[65].
Congenital Diaphragmatic Hernia
CDH is a disorder caused by an anatomical defect of the
fetal diaphragm. The abdominal viscera herniate into
the chest and cause fetal pulmonary hypoplasia. The
clinical spectrum of CDH ranges from minimally affected
infants who do well to severely affected infants who die
despite all aggressive interventions. Open fetal surgery
is hampered by technical problems. Tracheal occlusion
evolved as the mainstream antenatal therapy for this
disorder. The accumulated fluid within the fetal lungs
due to the tracheal occlusion restores lung volume and
improves the perinatal outcome in animal studies [66].
Fetoscopic tracheal occlusion is regarded as better than
the open method for tracheal occlusion in many animal
studies and, thus, much effort was put into improving
the devices and instrumentation of fetoscopy. The
endoluminal approach replaced the earlier externally
placed titanium clips in achieving tracheal occlusion as
fetoscopy progressed. For example, a percutaneous
single-port fetoscopic access system has excellent per-
formance in a sheep model, reducing the preterm deliv-
ery frequently encountered with the multiple-port feto-
scopic system [67].
However, despite considerable research into ante-
natal treatment of CDH, Harrison et al reported that
tracheal occlusion does not improve human fetal survival
nor reduce morbidity in fetuses with CDH [68]. Attempts
to treat this distressing disorder seemingly ended in
failure.
Fetal Anemia
Useful signs of fetal anemia include a sinusoidal pat-
tern in fetal heart rate (FHR) tracing as well as many
ultrasound markers including lengthened fetal liver,
increased fetal splenic perimeter, placentomegaly, hy-
drops fetalis, abnormal waveforms of cerebral arteries
(elevated peak systolic velocity), umbilical arteries (ab-
sent or reversed end-diastolic velocity), splenic artery,
thoracic aorta and ductus venosus (reversed A wave)
[69]. However, a low fetal hematocrit (< 30% is indicated
for fetal transfusion) in blood obtained from cordocen-
tesis is definitive proof of fetal anemia. Fetal transfu-
sion is the standard treatment for fetal anemia result-
ing from alloimmunization or human parvovirus B19
infection [70]. However, the efficacy of fetal transfusion
for fetal anemia is reduced in already hydropic fetuses
[71]. The incidence of anti-D Rhesus antibody is around
1 in 1,000 live births in the West but almost nil in East
Asians. Thus, fetal transfusion may only benefit a sub-
group of patients with fetal anemia in Taiwan, with
an etiology of human parvovirus B19 infection. Homo-
zygous _-thalassemia-1 is the main cause of non-
immune hydrops fetalis in Taiwan [24]. Intrauterine
transfusion can be used as a supportive treatment in
this condition but a more definitive treatment awaits
postnatal bone marrow transplantation [72]. In utero
stem cell transplantation has been proposed to treat
some lymphohematopoietic disorders, and the Euro-
pean Network for Fetal Transplantation (ENFET) was
established to study this highly experimental treatment
modality [73].
Conclusions
Fetal therapy should be aimed at promoting the health
of the fetus. Any heroic breakthrough in surgical skills
cannot be validated unless it is beneficial to the fetus.
Future developments rely on a better understanding of
the pathophysiology of fetal diseases. Minimally invasive
and endoscopic approaches to correctable anatomic
lesions as well as in utero cellular transplantation are the
most promising territories awaiting further explora-
tion [74]. Complications of monochorionic pregnancy
remain the major challenge to fetal therapists in the
future.
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